[ad_1]
An international team of scientists has discovered a new protein complex, Shieldin, that rebuilds damaged DNA and, if a mutation occurs, makes cancer cells resistant to PARP-based chemotherapy.
MedicalXpress reports that scientists They studied and analyzed breast cancer cells in which mutations occurred in the BRCA1 gene. Scientists have used the CRISPR / Cas9 system to detect genes that make the malignancy resistant to olaparib and talaoparib.
These compounds are attributed to PARP inhibitors that inhibit the activity of polymerase-poly (ADP-ribose) prevents death. In this case, the usual method of repairing the DNA is damaged.
The efficacy of PARP inhibitors inhibits mutations in the genes encoding the SHLD1, SHLD2 and SHLD3 proteins that form a complex that binds to directly damaged DNA termini. The damage to the protein compound forces the cells to use a new method of repairing the DNA. And avoids the effect of chemotherapy preparations aimed at inhibiting poly-polymerase (ADP-ribose).
[ad_2]
Source link
